Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
A composition and drug technology, applied in respiratory diseases, drug combinations, pharmaceutical formulations, etc., can solve problems such as lack of non-specific antidiarrheal treatment
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0097] Thirty male guinea pigs weighing 350-400 g were used for the experiments. Cough was induced by inhaling 30 μM capsaicin for 5 min using a nebulizer. The number of coughing episodes is counted within 15 minutes. Cough was induced twice: one before drug administration (baseline) and the second after drug administration. Distilled water (120 μL / guinea pig) was administered to the control group. A very low dose of anti-morphine antibody (40 μL / guinea pig) was administered to the second group. The complex (120 μL / guinea pig) was given a very low dose of anti-bradykinin antibody (ULDB), a very low dose of anti-histamine antibody (ULDH) and a very low dose of anti-morphine antibody (ULDM) to the third group. Three doses were administered orally (oral drops) at 120-minute intervals, the last 15 minutes before capsaicin-induced cough.
[0098] The study showed that the compound drug ULDB+ULDH+ULDM showed more significant antitussive effect than ULDM alone. The drugs suppres...
Embodiment 2
[0104] Tablets weighing 300 mg were used, which were saturated (6 mg / tablet) with a pharmaceutical composition containing an aqueous-alcoholic solution of an affinity-purified, potentiated form of the polyclonal rabbit antibody as follows: Bradykinin antibody (ULDB), very low dose antihistamine antibody (ULDH) and very low dose antimorphine antibody (ULDM); 12 、100 30 、100 50 Obtained as a result of extremely high dissolution times, corresponding to a mixture of C12, C30 and C50 homeopathic dilutions.
[0105]Evaluate the efficacy and safety of the compound compound ULDB+ULDH+ULDM based on the results of an open-label observational clinical study involving 107 subjects aged 19-82 years (average age 47.60±1.56 years) , who was being treated as an outpatient due to viral upper respiratory infection (URI) (acute pharyngitis / nasopharyngitis, acute laryngitis / laryngotracheitis) and / or lower respiratory infection (acute bronchitis). In addition to fever, intoxication, and catarrh...
Embodiment 3
[0120] Tablets weighing 300mg are used. The tablets were treated with an affinity-purified very low dose solution of anti-bradykinin polyclonal rabbit antibody (ULDB), anti-histamine polyclonal rabbit antibody (ULDH) and anti-morphine polyclonal rabbit antibody (ULDM). Dipping (6mg / tablet), each antibody as the matrix solution in 100 12 、100 30 、100 50 Obtained as a result of a high dilution, equivalent to a mixture of C12, C30 and C50 homeopathic dilutions.
[0121] Based on the upcoming multi-center open-label comparative clinical study, the efficacy and safety of the compound compound ULDB+ULDH+ULDM will be evaluated. Currently, data are available for 20 patients who have completed treatment. Fourteen patients received the compound compound ULDB+ULDH+ULDM at the dose of 2 tablets 3 times a day for the first three days and 1 tablet 3 times a day for the next 4 days. 6 patients received 1 tablet 3 times a day (codeine + sodium bicarbonate + licorice + herb Cassia lance...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 